

In 2015, the too high R&D attrition rate is not a fatality any more using a proven operational novel paradigm with 9 POC already produced.


Hello,

In 2015, the too high R&D attrition rate should not remain a fatality. CADI[™] Discovery, the "Mechanisms-Based Medicine" novel paradigm invented by BMSystems in 2004, is a proven pragmatic answer to run life sciences R&D programs better, faster, cheaper and safer.

Among <u>9 POC already produced</u>, two funded pharma spin-offs exploiting BMSystems' co-patented discoveries, <u>Pherecydes-Pharma</u> and <u>Theranexus</u>, are entering into clinical Phase I-II stage in 2015 with patented combinations of products.

These two milestones, and the 10 years of recurrent businesses with our clients, are a strong signal confirming that BMSystems, a SME created in 2004, profitable since 2006, succeeded to make the "Mechanisms-Based Medicine" paradigm fully operational with its CADI[™] Discovery platform that also addresses both efficacy and safety issues, the main culprits for the unacceptable R&D attrition rate.

Mechanisms-Based Medicine principles: The Global Discovery stepwise approach places diagnostic / therapies / prevention solutions & validation processes in the right order:



- Understanding the causal mechanisms of a disease should be the first objective. Finding the most adapted biomarkers and solutions are the necessary consequences of the first objective.
- To discover and understand these mechanisms, BMSystems' team builds heuristic non-mathematical in-silico models to generate novel concepts from scientific, medical & health data.
- BMSystems already generated, during the past 10 years a significant pipeline of internal Research programs.

© Bio-Modeling Systems 2015

www.bmsystems.net



What we invented and did for ourselves, we can do for your company in the biomedical, diagnostic, Pharma, cosmetics, nutrition domains.

If you believe that this too high attrition rate should not remain a fatality, do not hesitate to download our <u>full company and POC presentation</u>, our <u>scientific presentation</u> given at the 19th European Congress of Psychiatry – EPA 2011E and our <u>publications</u> and contact us, we may have a solution for your issues.

Two opportunities to meet us:

- March 9-11, 2015: <u>Bio-Europe Spring Paris France</u>: Manuel Gea, CEO BMSystems, invited as speaker to present its CADI[™] Discovery platform during the session: Translational medicine: From discovery to early stage drug development
- January 29, 2015: <u>Bio-Entrepreneur 2015 Paris France</u>: Manuel Gea, CEO BMSystems, invited to chair BioEntrepreneur Forum 2015: Innovative collaborations for cost effective novel therapies and prevention solutions combining diagnostics, therapies, connected devices and IT technologies.

Best regards

Manuel GEA Co-founder & CEO BMSystems

join my networks



About Bio-Modeling Systems (BMSystems):

Bio-Modeling Systems is a company dedicated to the discovery of cost-effective new diagnostic, therapeutic & prevention solutions for medicine, cosmetics, & nutrition applications.

BMSystems' answers to clients / partners' needs:

- Physiological / Diseases Mechanisms understanding Multi-Systems mechanisms Multi-Scale mechanisms description.
- Targets discovery & validation: Signatures of biomarkers discovery & validation. Marketing strategies rational support; Adaptive clinical trials rational support; Market Access rational support.
- New therapeutic / diagnostic / cosmetics strategies: New associations of molecules & devices New associations of existing molecules. Molecules / Devices Mechanisms of action
- R&D / Molecules / clinical programs evaluation: Next Phase GO / NO GO decision Novel Clinical phases end points / processes Drug (re) positioning /(re) profiling Drug side effects analysis for rescue Chemical entities safety issues (Allergy, PE, etc...).

BMSystems, created in 2004 and profitable since 2006, is the dual digital / biology company that invented the first operational "Mechanisms-based Medicine" platform, CADI™ Discovery, to enlarge and redefine the translational medicine paradigm and extract the maximum value from scientific, medical & health data. Our research programs address both efficacy and safety issues.

BMSystems has successfully completed programs in infectious diseases, oncology, neurology, psychiatry, dermatology, immunology and metabolic disorders, which led to patents and the creation of new companies exploiting these patents.

For more information and access to presentations & publications, please visit <u>http://www.bmsystems.net</u>.

*CADI (Computer Assisted Deductive Integration)